MEI Pharma Company Profile (NASDAQ:MEIP)

About MEI Pharma (NASDAQ:MEIP)

MEI Pharma logoMEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MEIP
  • CUSIP: N/A
  • Web: www.meipharma.com
Capitalization:
  • Market Cap: $99.03 million
  • Outstanding Shares: 36,950,000
Average Prices:
  • 50 Day Moving Avg: $2.63
  • 200 Day Moving Avg: $2.32
  • 52 Week Range: $1.34 - $3.26
P/E:
  • Trailing P/E Ratio: 38.29
  • Foreward P/E Ratio: -1.94
  • P/E Growth: 22.80
Sales & Book Value:
  • Annual Revenue: $23.25 million
  • Price / Sales: 4.26
  • Book Value: $1.38 per share
  • Price / Book: 1.94
Profitability:
  • EBITDA: $2.47 million
  • Net Margins: 11.48%
  • Return on Equity: 5.26%
  • Return on Assets: 4.55%
Debt:
  • Current Ratio: 11.38%
  • Quick Ratio: 11.38%
Misc:
  • Average Volume: 235,143 shs.
  • Beta: 1.59
  • Short Ratio: 0.64
 

Frequently Asked Questions for MEI Pharma (NASDAQ:MEIP)

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) issued its earnings results on Tuesday, September, 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. The company had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.60 million. MEI Pharma had a return on equity of 5.26% and a net margin of 11.48%. View MEI Pharma's Earnings History.

Where is MEI Pharma's stock going? Where will MEI Pharma's stock price be in 2017?

2 brokers have issued 1-year price objectives for MEI Pharma's shares. Their predictions range from $6.50 to $7.00. On average, they anticipate MEI Pharma's stock price to reach $6.75 in the next year. View Analyst Ratings for MEI Pharma.

What are analysts saying about MEI Pharma stock?

Here are some recent quotes from research analysts about MEI Pharma stock:

  • 1. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (9/9/2017)
  • 2. Cann analysts commented, "MEI Pharma and partner Helsinn presented positive findings at the European Hematology Association (EHA) meeting in Madrid, Spain from a genetic mutation analysis of patients in a phase II clinical study of the investigational drug pracinostat and azacitidine in acute myeloid leukemia (AML). These data were previously presented at ASCO in early June 2017. These data support our outlook that Helsinn could launch Pracinostat for the treatment of AML and other potential indications in calendar Q1 2022. Potential sales will be recognized in the form of royalty income by MEI Pharma." (6/26/2017)

Who are some of MEI Pharma's key competitors?

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the folowing people:

  • Christine Anna White M.D., Independent Chairman of the Board
  • Daniel P. Gold Ph.D., President, Chief Executive Officer, Director
  • Brian G. Drazba, Chief Financial Officer, Secretary
  • David M. Urso, Senior Vice President of Corporate Development, General Counsel
  • Robert D. Mass M.D., Chief Medical Officer
  • Charles V. Baltic III, Independent Director
  • Kevan E. Clemens Ph.D., Independent Director
  • Nicholas R. Glover Ph.D., Independent Director
  • Thomas C. Reynolds M.D. Ph.D., Independent Director
  • William Dodge Rueckert, Independent Director

How do I buy MEI Pharma stock?

Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MEI Pharma's stock price today?

One share of MEI Pharma stock can currently be purchased for approximately $2.68.


MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  196
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MEI Pharma (NASDAQ:MEIP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.75 (151.87% upside)
Consensus Price Target History for MEI Pharma (NASDAQ:MEIP)
Price Target History for MEI Pharma (NASDAQ:MEIP)
Analysts' Ratings History for MEI Pharma (NASDAQ:MEIP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/26/2017CannReiterated RatingBuy$6.50HighView Rating Details
6/14/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$7.00LowView Rating Details
8/2/2016WedbushReiterated RatingNeutral$2.00N/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for MEI Pharma (NASDAQ:MEIP)
Earnings by Quarter for MEI Pharma (NASDAQ:MEIP)
Earnings History by Quarter for MEI Pharma (NASDAQ MEIP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/5/2017Q4 2017($0.15)($0.12)$0.60 million$0.45 millionViewListenView Earnings Details
5/4/2017Q3 2017($0.03)($0.02)$5.00 million$4.51 millionViewN/AView Earnings Details
2/8/2017Q217($0.29)$0.32$1.25 million$17.20 millionViewN/AView Earnings Details
11/8/2016Q1 2017($0.14)($0.12)$0.63 million$1.10 millionViewN/AView Earnings Details
9/6/2016Q4 2016($0.20)($0.17)ViewN/AView Earnings Details
9/2/2015Q4 2015($0.23)($0.17)ViewN/AView Earnings Details
9/9/2014Q4 2014($0.37)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MEI Pharma (NASDAQ:MEIP)
2017 EPS Consensus Estimate: ($0.10)
2018 EPS Consensus Estimate: ($0.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20171($0.10)($0.10)($0.10)
Q1 20181($0.18)($0.18)($0.18)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.15)($0.15)($0.15)
Q4 20181($0.17)($0.17)($0.17)
Q1 20191($0.28)($0.28)($0.28)
Q2 20191($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MEI Pharma (NASDAQ:MEIP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for MEI Pharma (NASDAQ:MEIP)
Insider Ownership Percentage: 4.62%
Institutional Ownership Percentage: 17.93%
Insider Trades by Quarter for MEI Pharma (NASDAQ:MEIP)
Institutional Ownership by Quarter for MEI Pharma (NASDAQ:MEIP)
Insider Trades by Quarter for MEI Pharma (NASDAQ:MEIP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2015Vivo Ventures Vii, LlcMajor ShareholderSell390,572$1.84$718,652.48View SEC Filing  
1/21/2015Charles V Baltic IIIDirectorBuy5,000$3.81$19,050.00View SEC Filing  
12/9/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell79,085$6.01$475,300.85View SEC Filing  
12/8/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell9,004$6.05$54,474.20View SEC Filing  
6/30/2014Charles V Baltic IIIDirectorBuy2,000$6.56$13,120.00View SEC Filing  
10/29/2013Vivo Ventures Vii, LlcMajor ShareholderSell299,609$8.21$2,459,789.89View SEC Filing  
10/2/2013Vivo Ventures Vii, LlcMajor ShareholderSell581,646$10.16$5,909,523.36View SEC Filing  
8/16/2013Charles V Baltic IIIDirectorBuy2,600$6.82$17,732.00View SEC Filing  
6/28/2013Vivo Ventures Vii, LlcMajor ShareholderSell7,337$7.58$55,614.46View SEC Filing  
6/11/2013Vivo Ventures V, LlcMajor ShareholderSell13,727$7.80$107,070.60View SEC Filing  
5/16/2013Vivo Ventures Vii, LlcMajor ShareholderSell17,428$9.07$158,071.96View SEC Filing  
5/8/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell200,000$8.58$1,716,000.00View SEC Filing  
1/25/2013Charles V Baltic IIIDirectorBuy10,200$6.04$61,608.00View SEC Filing  
12/21/2012Charles V Baltic IIIDirectorBuy3,500$7.18$25,130.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for MEI Pharma (NASDAQ:MEIP)
Latest Headlines for MEI Pharma (NASDAQ:MEIP)
Source:
Loading headlines, please wait.

Social

Chart

MEI Pharma (MEIP) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.